Karen Scalzo-Inguanti - Search Results

Year	Number of Results
2008	1
2011	2
2012	2
2013	2
2016	2
2017	1
2021	0

1

Promising particle-based vaccines in cancer therapy.

Xiang SD, Scalzo-Inguanti K, Minigo G, Park A, Hardy CL, Plebanski M. Xiang SD, et al. Among authors: scalzo inguanti k. Expert Rev Vaccines. 2008 Sep;7(7):1103-19. doi: 10.1586/14760584.7.7.1103. Expert Rev Vaccines. 2008. PMID: 18767957 Review.

2

G-CSF and Neutrophils Are Nonredundant Mediators of Murine Experimental Autoimmune Uveoretinitis.

Goldberg GL, Cornish AL, Murphy J, Pang ES, Lim LL, Campbell IK, Scalzo-Inguanti K, Chen X, McMenamin PG, Maraskovsky E, McKenzie BS, Wicks IP. Goldberg GL, et al. Among authors: scalzo inguanti k. Am J Pathol. 2016 Jan;186(1):172-84. doi: 10.1016/j.ajpath.2015.09.008. Am J Pathol. 2016. PMID: 26718978 Free article.

3

A neutralizing anti-G-CSFR antibody blocks G-CSF-induced neutrophilia without inducing neutropenia in nonhuman primates.

Scalzo-Inguanti K, Monaghan K, Edwards K, Herzog E, Mirosa D, Hardy M, Sorto V, Huynh H, Rakar S, Kurtov D, Braley H, Wilson N, Busfield S, Nash A, Andrews A. Scalzo-Inguanti K, et al. J Leukoc Biol. 2017 Aug;102(2):537-549. doi: 10.1189/jlb.5A1116-489R. Epub 2017 May 17. J Leukoc Biol. 2017. PMID: 28515226

4

Therapeutic Targeting of the G-CSF Receptor Reduces Neutrophil Trafficking and Joint Inflammation in Antibody-Mediated Inflammatory Arthritis.

Campbell IK, Leong D, Edwards KM, Rayzman V, Ng M, Goldberg GL, Wilson NJ, Scalzo-Inguanti K, Mackenzie-Kludas C, Lawlor KE, Wicks IP, Brown LE, Baz Morelli A, Panousis C, Wilson MJ, Nash AD, McKenzie BS, Andrews AE. Campbell IK, et al. Among authors: scalzo inguanti k. J Immunol. 2016 Dec 1;197(11):4392-4402. doi: 10.4049/jimmunol.1600121. Epub 2016 Nov 2. J Immunol. 2016. PMID: 27807194 Free article.

5

Inert 50-nm polystyrene nanoparticles that modify pulmonary dendritic cell function and inhibit allergic airway inflammation.

Hardy CL, LeMasurier JS, Belz GT, Scalzo-Inguanti K, Yao J, Xiang SD, Kanellakis P, Bobik A, Strickland DH, Rolland JM, O'Hehir RE, Plebanski M. Hardy CL, et al. Among authors: scalzo inguanti k. J Immunol. 2012 Feb 1;188(3):1431-41. doi: 10.4049/jimmunol.1100156. Epub 2011 Dec 21. J Immunol. 2012. PMID: 22190179 Free article.

6

Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment.

Govindaraj C, Scalzo-Inguanti K, Madondo M, Hallo J, Flanagan K, Quinn M, Plebanski M. Govindaraj C, et al. Among authors: scalzo inguanti k. Clin Immunol. 2013 Oct;149(1):97-110. doi: 10.1016/j.clim.2013.07.003. Epub 2013 Jul 25. Clin Immunol. 2013. PMID: 23948613

7

TNFR2 Expression on CD25(hi)FOXP3(+) T Cells Induced upon TCR Stimulation of CD4 T Cells Identifies Maximal Cytokine-Producing Effectors.

Govindaraj C, Scalzo-Inguanti K, Scholzen A, Li S, Plebanski M. Govindaraj C, et al. Among authors: scalzo inguanti k. Front Immunol. 2013 Aug 6;4:233. doi: 10.3389/fimmu.2013.00233. eCollection 2013. Front Immunol. 2013. PMID: 23964278 Free PMC article.

8

CD38 identifies a hypo-proliferative IL-13-secreting CD4+ T-cell subset that does not fit into existing naive and memory phenotype paradigms.

Scalzo-Inguanti K, Plebanski M. Scalzo-Inguanti K, et al. Eur J Immunol. 2011 May;41(5):1298-308. doi: 10.1002/eji.201040726. Epub 2011 Apr 13. Eur J Immunol. 2011. PMID: 21469087 Free article.

9

Substantially modified ratios of effector to regulatory T cells during chemotherapy in ovarian cancer patients return to pre-treatment levels at completion: implications for immunotherapy.

Park A, Govindaraj C, Xiang SD, Halo J, Quinn M, Scalzo-Inguanti K, Plebanski M. Park A, et al. Among authors: scalzo inguanti k. Cancers (Basel). 2012 Jun 18;4(2):581-600. doi: 10.3390/cancers4020581. Cancers (Basel). 2012. PMID: 24213326 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results